Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.
Robertson SJ, Ibrahim MFK, Stober C, Hilton J, Kos Z, Mazzarello S, Ramsay T, Fergusson D, Vandermeer L, Mallick R, Arnaout A, Dent SF, Segal R, Sehdev S, Gertler S, Hutton B, Clemons M. Robertson SJ, et al. Among authors: gertler s. J Eval Clin Pract. 2019 Apr;25(2):196-204. doi: 10.1111/jep.13094. Epub 2019 Jan 23. J Eval Clin Pract. 2019. PMID: 30672056 Clinical Trial.
A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.
Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M. Ibrahim MFK, et al. Among authors: gertler s. Breast Cancer Res Treat. 2018 Apr;168(2):371-379. doi: 10.1007/s10549-017-4604-y. Epub 2017 Dec 6. Breast Cancer Res Treat. 2018. PMID: 29214415 Clinical Trial.
Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer-a patient survey.
LeVasseur N, Stober C, Ibrahim M, Gertler S, Hilton J, Robinson A, McDiarmid S, Fergusson D, Mazzarello S, Hutton B, Joy AA, McInnes M, Clemons M. LeVasseur N, et al. Among authors: gertler s. Curr Oncol. 2018 Aug;25(4):e305-e310. doi: 10.3747/co.25.3911. Epub 2018 Aug 14. Curr Oncol. 2018. PMID: 30111976 Free PMC article.
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. Addison CL, et al. Among authors: gertler s. Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18. Breast Cancer Res Treat. 2014. PMID: 24638849 Free PMC article. Clinical Trial.
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M. Jacobs C, et al. Among authors: gertler s. Breast Cancer Res Treat. 2016 Jan;155(1):77-84. doi: 10.1007/s10549-015-3646-2. Epub 2015 Dec 7. Breast Cancer Res Treat. 2016. PMID: 26643085 Clinical Trial.
65 results